Prostate-specific acid phosphatase versus acid phosphatase in monitoring patients with prostate cancer.
Serial levels of PAP and AcP activity were compared for their relative values in monitoring 57 early and 33 advanced prostate cancer patients. Several findings regarding the patients' disease status and the enzyme levels have been observed that may be beneficial to therapeutic management of these patients. They are: [1] an elevated PAP activity in disease recurrence and disease progression generally precedes an elevated AcP activity, and thus represents a more sensitive index for patients with early and advanced disease; [2] serial mean levels of PAP activity greater than the mean + 3 SD are more predictive for disease recurrence and progression than are those of AcP activity in both groups of patients; [3] PAP activity is a more sensitive monitor for changes in objective treatment response than is AcP activity; and [4] PAP is more specific than AcP for prostate, thus offering a more reliable marker to identify metastasis of unknown origin, or to confirm metastasis derived from a primary prostate tumor that may have been suggested by other non-prostate-specific marker[s]. In addition, data suggest a favorable prognosis for patients receiving therapy as inferred by a serial mean of PAP activity that is less than mean + 3 SD.
D000135:Acid Phosphatase / Q000097:blood*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003378:Counterimmunoelectrophoresis; D006801:Humans; D008297:Male; D008991:Monitoring, Physiologic; D009367:Neoplasm Staging; D011379:Prognosis; D011467:Prostate / Q000201:enzymology*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000532:radiotherapy; D012008:Recurrence; D013997:Time Factors
D000970:Antineoplastic Agents; D000135:Acid Phosphatase